Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886

• https://x.com/synovialjoints/status/2062210281942417906/photo/1

22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026

In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

• https://x.com/synovialjoints/status/2062208390512660905/photo/1

DIPSA RCT: diet in PsA 92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice Primary takeaway: amount of weight loss matters more than diet! -All groups lost modest weight 1–2.5 kg -All improved similarly in DAPSA -4 to -6 wk 24 -No differences for disease https://t.co/U0cxtdl2Yb

• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1
• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1
• https://x.com/AurelieRheumo/status/2062206463729156543/photo/1

#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6

• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1
• https://x.com/AurelieRheumo/status/2062205434908361008/photo/1

68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis 15 pts 1020 joints 35% affected joints clinically silent PET signal correlation w/ disease burden: DAPSA (ρ=0.66) CRP (ρ=0.69) Pilot study — not confirmed with US Needs validation but intriguing signal #OP068 https://t.co/nhS7PDZN0A

• https://x.com/AurelieRheumo/status/2062204893079716105/photo/1
• https://x.com/AurelieRheumo/status/2062204893079716105/photo/1

Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn

• https://x.com/JihaRheum/status/2062204122376343556/photo/1

TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn

• https://x.com/synovialjoints/status/2062204022908432498/photo/1

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y

• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1
• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1
• https://x.com/AurelieRheumo/status/2062203563351163212/photo/1

#EULAR2026 Abstr# OP06 9 TOGETHER-PsA: Adding tirzepatide to ixekizumab in #PsA + obesity achieved the primary composite (ACR50 + ≥10% weight loss) in 31.7% vs just 0.8% with IXE alone at 36 weeks (p<0.001). The first trial tackling PsA + obesity simultaneously @RheumNow https://t.co/0cDAj1y7OF

• https://x.com/synovialjoints/status/2062203020784361639/photo/1

Abst# OP068: 68Ga-RGD PET/CT imaging detected subclinical synovitis in 35% of joints that were clinically silent in #PsA. Molecular imaging may reveal the true burden of joint disease before it declares clinically. @RheumNow #EULAR2026 #PsoriaticArthritis

Small interventional synovial biopsy precision medicine study CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/ -DAPSA -13.5, -12.8 vs. -7.5 respectively Higher BL levels of tissue inflammation in Responders vs. NR More robust study design needed https://t.co/7jNff6lUJ6

• https://x.com/AurelieRheumo/status/2062200548602851820/photo/1

💊 Oral IL-23Ri for #PsA #PsO? ICONIC RCT (n=216): Yes! Icotrokinra improves pain & disease activity at week 16 #POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y

• https://x.com/Nellziade/status/2062192996485918946/photo/1

🛡️ Can secukinumab prevent #PsA? SERENA real-world study (n=1,334): Yes! 97% PsA-free at 5yrs #POS0051 #EULAR2026 @rheumnow